moneyheap
ADUS · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Addus HomeCare Corp. (ADUS) stock moving?
Addus reported Q3 2026 results on Nov 3: adjusted EPS of $1.83 beat the $1.79 estimate, while revenue of $387.7M was slightly below the $388.7M consensus. The earnings week brought a volume spike (508K shares on Nov 2 and 456K on Nov 3, versus roughly 200K to 300K in late October), and the stock hit an intraday high of $131.59 on Nov 5 before fading to a $122.42 close on Nov 9. It rebounded to $126.29 on Nov 10. Sell-side reaction was broadly positive: Truist, TD Cowen, BofA and UBS all raised targets to between $131 and $160 with Buy or equivalent ratings, and the average target rose to $134.92, roughly 7% above the last close. Barclays remains an outlier with an Underweight rating and a $101 target. The 10-Q was filed Nov 4, but the provided material gives no detail from it, and no new guidance text is included. The stock trades close to consensus targets, so much of the analyst upside is already in the price.
News behind the analysis
- Addus HomeCare Q3 Adj. EPS $1.83 Beats $1.79 Estimate, Sales $387.733M Miss $388.703M EstimateAdjusted EPS of $1.83 beat the $1.79 consensus, while revenue of $387.7M came in slightly below the $388.7M estimate.
- Addus HomeCare Reports Q3 2026 Financial ResultsThe company reported Q3 2026 adjusted EPS of $1.83 and revenue of $387.7M in its 8-K results release, furnished as Exhibit 99.1.
- Addus HomeCare Q3 2026 Earnings Call TranscriptManagement's commentary from the third-quarter 2026 earnings call, held the day results were released.
- Addus HomeCare Corporation Analyst Price Target IncreasedThe average 12-month analyst price target rose to $134.92, implying about 7% upside at the time.
- Barclays Adjusts Price Target for Addus HomeCareBarclays kept its Underweight rating and raised its price target to $101 from $96, the most bearish view among recent updates.
- BofA Securities Raises Price Target on Addus HomeCareBofA Securities raised its price target to $131 from $125 after the quarterly results.
- Truist Raises Price Target on Addus HomeCare to $148 From $135, Keeps Buy RatingTruist raised its price target to $148 from $135 and kept its Buy rating.
- TD Cowen Raises Price Target on Addus HomeCare to $145TD Cowen maintained its Buy rating and lifted its price target to $145 from $131.
- UBS Raises Price Target on Addus HomeCare to $160UBS raised its price target to $160 from $145 while maintaining its Buy rating, the highest target among recent updates.
- UBS Maintains Buy on Addus HomeCare, Raises Price Target to $160UBS reiterated its Buy rating and set a $160 price target following the third-quarter report.
About Addus HomeCare Corp.
Addus HomeCare is a Frisco, Texas-based company that provides care in people's homes, mostly non-medical personal care like bathing, dressing and meals for older adults and people with disabilities, plus hospice and home health services. What sets it apart is that most of its money comes from state Medicaid programs. It also grows by buying smaller local agencies, including HomeCourt (its entry into Indiana) in 2026 and a pending deal for AccentCare's personal care division.
How it makes money
It earns fees from government and private payers for hours of care delivered and patient-days of service. Personal care makes up roughly three-quarters of revenue and is paid mainly by state Medicaid programs and Medicaid managed-care plans. Hospice, paid largely by Medicare, is about a fifth of revenue, and home health is a small slice. Revenue for the first nine months of 2026 was about $1.13 billion, up about 8% from a year earlier.
What usually moves ADUS
- State Medicaid reimbursement rates and funding policy
- Personal care client volumes and hours of care
- Caregiver wages and labor availability
- Acquisition activity and integration (e.g., AccentCare personal care deal)
- Medicare hospice rate updates and census